San Diego, CA, June 15, 2022 – Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today presented new preclinical data on LASN01, a monoclonal antibody targeting IL-11 receptor (IL-11R), in preclinical models of skin fibrosis at the Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado. The data build upon the results in models of lung fibrosis recently presented at the American Thoracic Society (ATS) conference in May.

Continue reading “Lassen Therapeutics Presents New Preclinical Data on IL-11 Receptor-blocking as a Novel Therapeutic Approach for Skin Fibrosis at Keystone Symposia Conference”

San Diego, CA, May 26, 2022 – Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced plans to present a poster on IL-11 receptor-blocking as a novel therapeutic approach for lung fibrosis at the upcoming Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado, June 12-16, 2022.

Continue reading “Lassen Therapeutics Announces Presentation at Keystone Symposia Conference on IL-11 Receptor-blocking as a Novel Therapeutic Approach for Lung Fibrosis”

San Diego, CA, October 07, 2021 – Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced the appointment of a highly experienced industry executive and recognized clinical thought leaders to its team.

Continue reading “Lassen Therapeutics Announces the Appointment of a Highly Experienced Biotech Executive to its Board of Directors and the Expansion of its Scientific and Clinical Advisory Board with Leading Experts in Pulmonary Fibrosis and Clinical Development”

Goal is to generate proof of principle and mechanistic understanding of the efficacy of antibodies targeting IL-11 receptor in idiopathic pulmonary fibrosis

San Diego, CA, March 25, 2021 – Lassen Therapeutics a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, today announced a collaboration with Cedars Sinai Medical Center. The collaboration will study the role of IL-11 signaling and its inhibition in lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), and the potential therapeutic effect of monoclonal antibodies that block this signaling in preclinical models.

Continue reading “Lassen Therapeutics Announces Collaboration with Cedars Sinai Medical Center to Study the Role of IL-11 Signaling and Inhibition in Preclinical Models of Lung Fibrosis”

Goal is to demonstrate proof of principle in targeting IL-11 receptor as a potential treatment of primary tumors and metastatic lesions

 San Diego, CA, February 9, 2021 – Lassen Therapeutics a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, today announced a collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) in Melbourne, Australia. The collaboration will study the role of IL-11 signaling and assess the potential of monoclonal antibodies that block IL-11 signaling in preclinical models of triple negative breast cancer.

Continue reading “Lassen Therapeutics Announces Collaboration with the Olivia Newton-John Cancer Research Institute to Study the Role of IL-11 Signaling and Inhibition in Preclinical Models of Breast Cancer”

San Diego, CA, December 16, 2020 – Lassen Therapeutics, a biotech company developing innovative antibodies as potential treatments for fibrosis, rare diseases and oncology, today announced the formation of its scientific advisory board. Lassen’s lead molecule, LASN01, is a best-in-class monoclonal antibody targeting the interleukin-11 (IL-11) receptor.  The newly formed SAB will work closely with Lassen’s leadership team to further advance research and development of the company’s innovative pipeline.

Continue reading “Lassen Therapeutics Announces Formation of Scientific Advisory Board”